Prot # VX11-950-114: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype

Project: Research project

Project Details

StatusFinished
Effective start/end date3/8/123/8/16

Funding

  • Parexel (VX11-950-114)
  • Vertex Pharmaceuticals Incorporated (VX11-950-114)